Verve Therapeutics Inc
NASDAQ:VERV
Income Statement
Earnings Waterfall
Verve Therapeutics Inc
Income Statement
Verve Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
2
+109%
|
3
+72%
|
5
+63%
|
8
+40%
|
12
+54%
|
16
+36%
|
21
+29%
|
24
+18%
|
32
+33%
|
60
+84%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(41)
|
(47)
|
(58)
|
(72)
|
(87)
|
(105)
|
(130)
|
(151)
|
(168)
|
(195)
|
(214)
|
(225)
|
(235)
|
(238)
|
(243)
|
(251)
|
(261)
|
(268)
|
|
| Selling, General & Administrative |
(5)
|
(7)
|
(10)
|
(14)
|
(19)
|
(24)
|
(29)
|
(33)
|
(38)
|
(43)
|
(47)
|
(49)
|
(50)
|
(52)
|
(53)
|
(55)
|
(57)
|
(58)
|
|
| Research & Development |
(35)
|
(40)
|
(48)
|
(58)
|
(68)
|
(81)
|
(101)
|
(119)
|
(130)
|
(153)
|
(167)
|
(175)
|
(185)
|
(186)
|
(190)
|
(196)
|
(204)
|
(210)
|
|
| Operating Income |
(41)
N/A
|
(47)
-16%
|
(58)
-22%
|
(72)
-25%
|
(87)
-21%
|
(105)
-21%
|
(130)
-24%
|
(151)
-16%
|
(166)
-10%
|
(192)
-16%
|
(208)
-9%
|
(217)
-4%
|
(223)
-3%
|
(222)
+1%
|
(222)
0%
|
(227)
-2%
|
(229)
-1%
|
(208)
+9%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
7
|
12
|
17
|
21
|
23
|
26
|
28
|
29
|
29
|
26
|
|
| Total Other Income |
(5)
|
(6)
|
(41)
|
(40)
|
(33)
|
(32)
|
4
|
0
|
1
|
1
|
(1)
|
3
|
0
|
(0)
|
2
|
1
|
2
|
2
|
|
| Pre-Tax Income |
(46)
N/A
|
(53)
-17%
|
(99)
-85%
|
(113)
-14%
|
(120)
-7%
|
(137)
-14%
|
(125)
+9%
|
(148)
-18%
|
(157)
-7%
|
(179)
-14%
|
(192)
-7%
|
(193)
0%
|
(200)
-4%
|
(196)
+2%
|
(192)
+2%
|
(197)
-2%
|
(198)
-1%
|
(181)
+9%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(46)
|
(53)
|
(99)
|
(113)
|
(120)
|
(137)
|
(125)
|
(148)
|
(157)
|
(179)
|
(192)
|
(193)
|
(200)
|
(197)
|
(193)
|
(197)
|
(199)
|
(181)
|
|
| Net Income (Common) |
(46)
N/A
|
(53)
-17%
|
(99)
-85%
|
(113)
-14%
|
(120)
-7%
|
(137)
-14%
|
(125)
+9%
|
(148)
-18%
|
(157)
-7%
|
(179)
-14%
|
(192)
-7%
|
(193)
0%
|
(200)
-4%
|
(197)
+2%
|
(193)
+2%
|
(197)
-2%
|
(199)
-1%
|
(181)
+9%
|
|
| EPS (Diluted) |
-0.99
N/A
|
-1.15
-16%
|
-2.05
-78%
|
-2.34
-14%
|
-2.48
-6%
|
-2.84
-15%
|
-2.58
+9%
|
-2.58
N/A
|
-2.91
-13%
|
-2.9
+0%
|
-3.1
-7%
|
-3.05
+2%
|
-3.12
-2%
|
-2.36
+24%
|
-2.28
+3%
|
-2.32
-2%
|
-2.35
-1%
|
-2.03
+14%
|
|